In a nutshell This study evaluated the long-term outcomes of first-line treatment in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The authors concluded that survival among these patients was similar to that of the general population. Some background NLPHL is a rare type of Hodgkin lymphoma. When diagnosed, most...
Read More
In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...
Read More
In a nutshell This study aimed to investigate if 18F-FDG PET/CT (ePET1) imaging can predict overall survival in patients with relapsed or unresponsive (refractory) Hodgkin lymphoma who have been treated with nivolumab. This study concluded that ePET1 assessment can predict overall survival in these patients. Some...
Read More
In a nutshell This study evaluated the long-term outcomes of chemotherapy plus radiotherapy for patients with early-stage classical Hodgkin's lymphoma (cHL). The authors found that this treatment combination was highly effective, with minimal late side effects. Some background Early-stage (stage 1 to 2) cHL is usually treated with a...
Read MoreIn a nutshell This study aimed to investigate the long-term outcomes for patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the 2 clinical trials. This study concluded that the outcomes for these patients who received Hodgkin lymphoma directed first-line treatment was good. Some...
Read More
In a nutshell This study evaluated the risk factors associated with delayed engraftment in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some...
Read MoreIn a nutshell This study aimed to investigate the association of uric acid levels before a stem cell transplant and patient outcomes. This study concluded that high uric acid levels before the transplant led to increased mortality. Some background Uric acid is a product of metabolic breakdown and is a normal component of urine. It...
Read More
In a nutshell This study compared the effectiveness of brentuximab vedotin (Adcetris) to chemotherapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding after a stem cell transplant (SCT). This study concluded that patients treated with brentuximab vedotin had better outcomes compared to patients in the...
Read More
In a nutshell This study evaluated whether PET scanning after chemotherapy might help predict outcomes and guide treatment for patients with early-stage Hodgkin's lymphoma (HL). This study found that PET scanning can help identify high-risk patients after chemotherapy. Some background Chemotherapy combined with radiotherapy is the standard of...
Read More
In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...
Read More
In a nutshell This study evaluated camrelizumab (SHR 1210) for patients with classical Hodgkin's Lymphoma (cHL) that has come back or is resisting treatment. The authors concluded that this drug is a safe and effective treatment for these patients. Some background After initial treatment, 5-10% of patients with cHL do not...
Read More
In a nutshell This study evaluated the outcomes of allogeneic stem cell transplantation (SCT) in patients with classical Hodgkin’s lymphoma (CHL) that was refractory (resistant to treatment) or had relapsed. The study found that patients in complete remission (no signs of cancer) when they received the transplant had better outcomes. Some...
Read More
